Innovent Biologics (HK:1801) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Innovent Biologics has entered into an exclusive global license agreement with Roche for the development and commercialization of its novel DLL3-targeted antibody drug conjugate, IBI3009. The deal includes an upfront payment of $80 million to Innovent, with potential milestone payments reaching $1 billion, alongside tiered royalties. This partnership aims to provide new treatment options for advanced small cell lung cancer.
For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.
